The Food and Drug Administration (FDA) can maintain its high bar for safety and efficacy, and also cut the waste and ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Once someone decides they need an abortion, they will go to great lengths to get one because they know it is the right ...

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

The FDA's breakthrough devices program helps the industry with faster review times, but the benefit to patients is unclear.

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Novo Nordisk teamed up with the company in a bid to broaden access to Wegovy and get patients back onto the US Food and Drug Administration (FDA)-approved product.

Novo Nordisk plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.